A-1331852

A-1331852

Catalog Number:
L002371470APE
Mfr. No.:
APE-B6164
Price:
$323
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Ki: 6 nM for BCL-2 TR-FRETA-1331852 is a potent and selective inhibitor of BCL-XL.Apoptosis is reported to be regulated by a family of closely related proteins exemplified by B cell lymphoma protein 2 (BCL-2), which is the first discovered family member. BCL-2 family proteins are divided by one to four BCL-2 homology motifs and can be further subdivided into pro- and antiapoptotic subsets.In vitro: A-1331852 was identified as a potent BCL-XL inhibitor demonstrating cellular activity 10- to 50-fold more potent than its analog A-1155463 and the previouly reported BCL-XL inhibitor, navitoclax, respectively. Moreover, A-1331852 could selectively disrupt BCL-XL–BIM complexes and induce the apoptosis hallmarks in BCL-XL–dependent Molt-4 cells with median IC50 values in the low nanomolar range but did not affect MEF cells without BAK or BAX [1]. In vivo: Previous animal study found that A-1331852 could demonstrate antitumor efficacy in the Molt-4 xenograft model, such as tumor regressions as a single agent. In addition, in the NCI-H1963.FP5 xenograft model of SCLC, it was found that A-1331852 combined with venetoclax was able to recapitulate the efficacy of navitoclax [1]. Clinical trial: Up to now, A-1331852 is still in the preclinical development stage.

      • Properties
        • Alternative Name
          3-(1-(adamantan-1-ylmethyl)-5-methyl-1H-pyrazol-4-yl)-6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)picolinic acid
          CAS Number
          1430844-80-6
          Molecular Formula
          C38H38N6O3S
          Molecular Weight
          658.81
          Purity
          98.00%
          Solubility
          ≥113.6 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Shahbandi A, Rao SG, et al. "BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer." Cell Death Differ. 2020;10.1038/s41418-020-0564-6. PMID:32457483

    We Also Recommend

    FRAX486

    $209

    MI-136

    $461

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.